Updated 2/2021

	MercyOne Primghar, a Health Ministry of Trinity Health, presents the following COVID-19 (Corona Virus) test price information for consumers to consider the cost of testing in our facility(ies).	Please follow the Financial Assistance Policy for MercyOne Primghar aligned with 501R guidelines as stated in COVID-19 Self-Pay Price communication document: https://www.mercyone.org/primghar/for-patients/billing-and-financial-information/financial-assistance		
CPT/HCPCS Code	CPT Code Description	Consumer friendly description	Standard Price	Cash Price
C9803	COVID-19 Specimen collection, any source, nasal, blood, saliva	COVID-19 Specimen collection, any source, nasal, blood, saliva	\$25	\$18.33
	Molecular Diagnosticc Testing			
U0001	CDC 2019 novel coronavirus (2019-ncov) real- time rt-pcr diagnostic panel	CDC COVID-19 VIRUS DETECTION TEST KIT	na	na
	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or			
U0002	subtypes (includes all targets), non-cdc Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19 VIRUS DETECTION TEST (NON PCR)	\$120	\$88.00
87635	[COVID-19]), amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19 VIRUS DETECTION TEST (BY PCR)	na	na
87636	[COVID-19]) and influenza virus types A and B, multiplex amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome	COVID-19, influenza A and B, VIRUS DETECTION TEST (BY PCR)	na	na
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified	COVID-19, influenza A and B, Respiratory	200	na
87637	probe technique	Syncytial VIRUS DETECTION TEST (BY PCR)	na	

	•		
Infectious agent detection by nucleic acid (DNA			
or RNA); severe acute respiratory syndrome			
coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
[COVID-19]), amplified probe technique, making			
use of high throughput technologies as	COVID-19 VIRUS DETECTION TEST (BY PCR)		
described by CMS-2020-01-R	High throughput, High Volume analyzer	\$375	\$281.25
2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV			
(COVID-19), any technique, multiple types or			
subtypes (includes all targets), non-CDC, making			
use of high throughput technologies as	COVID-19 VIRUS DETECTION TEST (NON PCR)		
described by CMS-2020-01-R.	High throughput, High Volume analyzer	na	na
Infectious agent detection by nucleic acid (DNA			
or RNA); severe acute respiratory syndrome			
coronavirus 2 (SARS-CoV-2) (Coronavirus disease			
[COVID-19]), amplified probe technique, CDC or			
non-CDC, making use of high throughput			
·	Use of HIGH Throughput technology with		
· ·	COVID VIRUS Detection resulted within 48		
U0003 or U0004)	hours	\$25	\$18.33
Molecular Testing Panel Codes that include		-	
COVID-19			
Infectious disease (bacterial or viral respiratory			
tract infection), pathogen specific nucleic acid			
(DNA or RNA), 22 targets including severe acute			
respiratory syndrome coronavirus 2 (SARS-CoV-			
2), qualitative RT-PCR, nasopharyngeal swab,			
each pathogen reported as detected or not	BIOFIRE 2.1 Respiratory Viral Panel including		
detected	COVID-19 (BY PCR)	\$375	\$275.00
Infectious disease (bacterial or viral respiratory			
tract infection), pathogen-specific nucleic acid			
(DNA or RNA), 22 targets including severe acute			
respiratory syndrome coronavirus 2 (SARS-CoV-			
2), qualitative RT-PCR, nasopharyngeal swab,			
each pathogen reported as detected or not	QIAstat-Dx Respiratory SARS-CoV-2 Panel		
detected	including COVID-19 (BY PCR)	na	na
	or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. (List separately in addition to either HCPCS code U0003 or U0004) Molecular Testing Panel Codes that include COVID-19 Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not	or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. (List separately in addition to either HCPCS code U0003 or U0004) Molecular Testing Panel Codes that include COVID-19 Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not qualitative RT-PCR, nasopharyngeal swab, each pat	or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R High throughput, High Volume analyzer \$375 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. COVID-19 VIRUS DETECTION TEST (NON PCR) High throughput, High Volume analyzer na described by CMS-2020-01-R. COVID-19 VIRUS DETECTION TEST (NON PCR) High throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMS-2020-01-R. Use of HIGH Throughput, High Volume analyzer na described by CMID-19 VIRUS DETECTION TEST (NON PCR) High throughput, High Volume analyzer na described by CMID-19 VIRUS DETECTION TEST (NON PCR) High throughput, High Volume analyzer na described by CMID-19 VIRUS DETECTION TEST (BY PCR) High throughput, High Volume analyzer na described by CMID-19 VIRUS DETECTION TEST (BY PCR) High throughput, High Volume analyzer na described by CMID-19 VIRUS Detection resulted within 48 hours severally in addition to either HCPCS code Use of HIGH Throughput technology with COVID-19 VIRUS Detection resulted within 48 hours severally in addition to either HCPCS code Use of HIGH Throughput technology wit

	1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1			1
	Infectious disease (bacterial or viral respiratory			
	tract infection) pathogen-specific DNA and RNA,			
	21 targets, including severe acute respiratory			
	syndrome coronavirus 2 (SARS-CoV-2), amplified			
	probe technique, including multiplex reverse			
	transcription for RNA targets, each analyte	ePlex® Respiratory Pathogen Panel 2		
0225U	reported as detected or not detected	including COVID-19 (NON PCR)	na	na
	Infectious disease (viral respiratory tract			
	infection), pathogen-specific RNA, 3 targets			
	(severe acute respiratory syndrome coronavirus			
	2 [SARS-CoV-2], influenza A, influenza B), upper	Cepheid Xpert® Xpress Repiratory Viral		
	respiratory specimen, each pathogen reported	Panel including COVID-19, Infuenza A & B		
0240U	as detected or not detected	(PCR)	na	na
	Infectious disease (viral respiratory tract			
	infection), pathogen-specific RNA, 4 targets			
	(severe acute respiratory syndrome coronavirus			
	2 [SARS-CoV-2], influenza A, influenza B,			
	respiratory syncytial virus [RSV]), upper	Cepheid Xpert® Xpress Repiratory Viral		
	respiratory specimen, each pathogen reported	Panel including COVID-19, Infuenza A & B,		
0241U	as detected or not detected	Respiratory Syncytial (PCR)	na	na
	Antigen Testing Codes		na	na
	Infectious agent antigen detection by			
	immunoassay technique, (eg, enzyme			
	immunoassay [EIA], enzyme-linked			
	immunosorbent assay [ELISA], fluorescence			
	immunoassay [FIA], immunochemiluminometric			
	assay [IMCA]) qualitative or semiquantitative;			
	severe acute respiratory syndrome coronavirus	Corona Virus/COVID-19 Antigen testing to		
87426	(e.g., SARS-CoV, SARS-CoV-2 [COVID-19])	detect virus	\$83	\$61.00
	Infectious agent antigen detection by			
	immunoassay technique, (eg, enzyme			
	immunoassay [EIA], enzyme-linked			
	immunosorbent assay [ELISA], fluorescence			
	immunoassay [FIA], immunochemiluminometric			
	assay [IMCA]) qualitative or semiquantitative;			
	severe acute respiratory syndrome coronavirus			
	(eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and	Corona Virus/COVID-19, Influenza A & B		
87428	influenza virus types A and B	Antigen testing to detect virus	na	na

	Infectious agent antigen detection by immunoassay with direct optical (ie, visual)			
	observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19 Antigen Test By Rapid Visual		
87811	[COVID-19])	Detection	na	na
07011	Antibody Testing Codes	Detection	na	na
	Immunoassay for infectious agent antibody(ies),			
	qualitative or semiquantitative, single step			
	method (eg, reagent strip); severe acute	COVID-19 VIRUS Antibody Detection Test,		
	respiratory syndrome coronavirus 2 (SARS-CoV-	single step (prior Infection of COVID-19),		
86328	2) (Coronavirus disease [COVID-19])	presence or absence	na	na
	Antibody; severe acute respiratory syndrome	COVID-19 VIRUS Antibody Detection Test,		
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	complex (prior Infection of COVID-19),		
86769	[COVID-19])	presence or absence	\$45	\$33.00
	Severe acute respiratory syndrome coronavirus			
	2 (SARS-CoV-2) (Coronavirus disease [COVID-	COVID-19 VIRUS Antibody Quantitiative Test,		
86413	19]) antibody, quantitative	(prior Infection of COVID-19)	na	na
	Neutralizing antibody, severe acute respiratory	COVID-19 VIRUS Blocking Antibody Test,		
	syndrome coronavirus 2 (SARS-CoV-2)	(immunoresponse to block future infections		
86408	(Coronavirus disease [COVID-19]); screen	of COVID-19), Presence or absence	na	na
	Neutralizing antibody, severe acute respiratory	COVID-19 VIRUS Blocking Antibody		
	syndrome coronavirus 2 (SARS-CoV-2)	Quantitative Test, (immunoresponse to block		
86409	(Coronavirus disease [COVID-19]);titer	future infections of COVID-19)	na	na
	Antibody, severe acute respiratory syndrome			
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease	COVID-19 Antibody Test, performed by		
0224U	[COVID-19]), includes titer(s), when performed	Mount Sinai Laboratory	na	na
		COVID-19 VIRUS Blocking Antibody Test,		
	Surrogate viral neutralization test (sVNT), severe	(immunoresponse to block future infections		
	acute respiratory syndrome coronavirus 2	of COVID-19), Presence or absence, Tru-		
	(SARS-CoV-2) (Coronavirus disease [COVID-19]),	ImmuneTM, Ethos Laboratories, GenScript®		
0226U	ELISA, plasma, serum	USA Inc	na	na